Michael Sullivan is the Continental President (Oceania) of the International Society of Paediatric Oncology (SIOP) and represents SIOP on the WHO Global Childhood Cancer Initiative. He trained in Paediatrics and Paediatric Oncology in New Zealand and Australia, including a PhD in 1998 on cancer epigenetics and DNA methylation. From 1998-2012 he was director of the Children’s Cancer Research Group in New Zealand and in 2001he was one of 5 cofounders of Pacific Edge, a biotech company using the emerging high-throughput technologies for cancer biomarker discovery. He moved to Melbourne in 2013 to to lead the development of the Solid Tumour and Neuro-Oncology Programs at RCH.
His particular clinical and research interests are in treatment of childhood embryonal tumours; hepatoblastoma, neuroblastoma and CNS tumours. He is an investigator in multiple international collaborative clinical trials applying precision medicine to the diagnosis and treatment of cancer in children. More recently, Professor Sullivan has led the development of a Global Child Cancer Program at RCH to support child cancer care in Oceania and SE Asia.